Table 2.

Studies summarizing dupilumab use in BP.

Author	Drug	No. of Patients	Dose	Primary Endpoint	Safety	Associated Therapies	Phase of Study
NCT04206553 [37]	Dupilumab	98 (estimated)	Loading dose administered SC, followed by once every 2 weeks (Q2W)	Proportion of patients achieving sustained remission	-	-	Phase 2/3
Kaye A. et al., (2018) [38]	Dupilumab	1	600 mg week 0, 300 mg every other week	Complete remission	NA	No	Case report
Seyed Jafari S. et al., (2020) [39]	Dupilumab	1	600 mg week 0, 300 mg every other week	Complete remission	NA	Omalizumab, MFM, TCS	Case report
Seidman S. et al., (2019) [40]	Dupilumab	1	600 mg week 0, 300 mg every other week	Improved pruritus, complete remission	NA	PDN, MFM, DXC, nicotinamide, TCS	Case report
Abdat R. et al., (2020) [41]	Dupilumab	13	600 mg week 0, 300 mg every other week; 600 mg week 0, 300 mg weekly. 600 mg week 0, 300 mg every 12 days;	7/13 Disease clearance 5/13 Satisfactory disease control 1/13 No response	NA	MTX, PDN, IVIg	Case series
Zhang Y et al., (2021) [42]	Dupilumab	8	600 mg week 0, 300 mg every other week	Complete remission (62.5%)	NA	AZA, MPDSN	Comparative Study

MPDSN = metilprednisolone; MFM = mycophenolate mofetil; MTX = methotrexate; PDN = prednisone; IVIg = intravenous immunoglobulin; AZA = azathioprine; DXC = doxycycline; TCS = topical corticosteroids.